Ann: Appendix 4E and Annual Report, page-42

A bit of irony here .... one of our customers got EUA for treating certain Covid19 patients last week using a product with our sensor in it.
Liked by Tim Stucchi



I have picked this thread to post this for a reason.
The annual report looked good, WITHOUT NanoDX.



There was no commentary on NanoDX in the annual report.
I wrote the following comment

Remembering this commentary ( other than outlook paragraph above ) is about the financial year gone. I'm assuming any sales to NanoDX in the last financial year were immaterial and would be referred to as R&D income. Two customers were above 10%, AbioMed and Nova Biomedical. The good news is Nova Biomedical are progressing well .... that's about 250,000 sensors ( $1.50 ea ), well past prototype stage! And we have been told, ramping to material volume in the first quarter this financial year ... the first quarterly is looking like a ripper.

(i) Information about major customers
The Group had the following major customers with revenues amounting to 10 percent or more of total group revenues:
Consolidated
2021
US$
Customer A (MicroDevices) $1,933,792
Customer B (MicroDevices) $369,000

If this business can get to breakeven on AbioMed and Nova BioMedical, then it creates a platform from which it can rise from the ashes.
A company worth more than $8M MC.
I'll hold the shares I have left until the quarterly ... and the re-assess.

GLTAH